Xuanzhu Biopharma ordered to pay RMB 9.33 million in CIETAC arbitration award

PUBT · 1d ago
Xuanzhu Biopharma ordered to pay RMB 9.33 million in CIETAC arbitration award
  • Xuanzhu Biopharmaceutical received a final CIETAC arbitration award on July 15, 2026 over a May 21, 2021 technology transfer contract.
  • Tribunal ordered payment of about RMB 9.33 million; the award is final and binding.
  • Dispute followed steep price declines tied to China’s centralized drug procurement, triggering disagreements over R&D deliverables and GMP inspection progress.
  • Provision booked in 2025 financial statements; management expects no material impact on 2026 interim results or ongoing operations.
  • Product was a non-core introduced generic; commercialization work is being discontinued due to limited market potential.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260719-12248957), on July 19, 2026, and is solely responsible for the information contained therein.